Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

New cancer therapy target found in mitochondria for potential treatment of blood cancers

New cancer therapy target found in mitochondria for potential treatment of blood cancers

$Phase 1 interim results for anti-BCMA CAR T-cell therapy in relapse refractory multiple myeloma$

Phase 1 interim results for anti-BCMA CAR T-cell therapy in relapse refractory multiple myeloma

Researchers identify ways to predict and avoid radiotherapy side effects

Researchers identify ways to predict and avoid radiotherapy side effects

Radiotherapy after chemotherapy may improve survival for patients with advanced Hodgkin’s lymphoma

Radiotherapy after chemotherapy may improve survival for patients with advanced Hodgkin’s lymphoma

Researchers reveal key to targeting dormant cancer cells

Researchers reveal key to targeting dormant cancer cells

First major study of proteins in patients with acute lymphoblastic leukaemia

First major study of proteins in patients with acute lymphoblastic leukaemia

Two birds, one stone: Drug combo may prove effective against second type of leukaemia

Two birds, one stone: Drug combo may prove effective against second type of leukaemia

Blood cancer's Achilles' heel opens door for new treatments

Blood cancer's Achilles' heel opens door for new treatments

Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies

Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies

More from ecancer